Mifepristone in Children With Refractory Cushing's Disease

NCT01925092 ↗

Phase 3 Withdrawn Corcept Therapeutics Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab

NaSingle-groupOpen-labelTreatment

Summary

Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease.

Timeline

Start: 2013-08
Primary completion: 2016-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mifepristone	Small molecule	—	—

Mifepristone in Children With Refractory Cushing's Disease

Summary

Timeline

Drugs

Indications